493 related articles for article (PubMed ID: 25263215)
1. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
3. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Farngren J; Persson M; Ahrén B
Diabetes Obes Metab; 2018 Aug; 20(8):1911-1920. PubMed ID: 29645341
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
[TBL] [Abstract][Full Text] [Related]
5. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
[TBL] [Abstract][Full Text] [Related]
6. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
[TBL] [Abstract][Full Text] [Related]
7. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
9. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
[TBL] [Abstract][Full Text] [Related]
12. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
14. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
15. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes.
Korzon-Burakowska A; Hopkins D; Matyka K; Lomas J; Pernet A; Macdonald I; Amiel S
Diabetes Care; 1998 Feb; 21(2):283-90. PubMed ID: 9539997
[TBL] [Abstract][Full Text] [Related]
16. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
Okuda I; Wilson TH; Yue L; Nakajima H; Carr MC; Tsuboi M; Nino A; Seino Y
Curr Med Res Opin; 2017 Mar; 33(3):431-438. PubMed ID: 27852119
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia.
George PS; McCrimmon RJ
Diabet Med; 2016 Sep; 33(9):1283-90. PubMed ID: 26642301
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
[TBL] [Abstract][Full Text] [Related]
19. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
20. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
